U.S. Markets close in 3 hrs 28 mins

Eli Lilly reports Q4 Zyprexa sales down 49% to $384M

In Q4, Zyprexa sales totaled $384.8M, a decrease of 49% due to the loss of patent exclusivity in the U.S. and most major international markets, partially offset by growth in Japan. U.S. sales of Zyprexa decreased 80% to $60.1M. Zyprexa sales in international markets decreased 29%, to $324.7M.